Trial Profile

A Phase 1a/b Clinical trial evaluating VYN201 in healthy volunteers and in vitiligo patients

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VYN 201 (Primary)
Indications Vitiligo
Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept
Sponsors VYNE Therapeutics; Yarrow Bioscience

Most Recent Events

27 Jul 2026 According to a Yarrow Bioscience media release, Yarrow Bioscience has merged with VYNE Therapeutics to form Yarrow Bioscience.
01 May 2024 According to a VYNE Therapeutics media release, abstract reporting Phase 1b data for VYN201, have been selected for presentation at the 81st Annual Meeting of the Society for Investigative Dermatology (SID), being held May 15-18, 2024 in Dallas, TX, USA.
29 Feb 2024 According to a VYNE Therapeutics media release, results will be at presented the Foundation's annual symposium held on March 7, 2024 in San Diego.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com